Discounted Cash Flow (DCF) Analysis Unlevered
Calithera Biosciences, Inc. (CALA)
$0.05
+0.05 (+0.00%)
All numbers are in Millions, Currency in USD
Operating Data
Year A/P | 2018 Actual | 2019 Projected | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 22.25 | - | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| EBITDA | -57.28 | - | - | - | - | - | - | - | - | - |
| EBITDA (%) | ||||||||||
| EBIT | -57.79 | - | - | - | - | - | - | - | - | - |
| EBIT (%) | ||||||||||
| Depreciation | 0.51 | - | - | - | - | - | - | - | - | - |
| Depreciation (%) |
Balance Sheet Data
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Total Cash | 136.15 | - | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Cash (%) | ||||||||||
| Account Receivables | 2 | - | - | - | - | - | - | - | - | - |
| Account Receivables (%) | ||||||||||
| Inventories | -2 | - | - | - | - | - | - | - | - | - |
| Inventories (%) | ||||||||||
| Accounts Payable | 1.25 | - | - | - | - | - | - | - | - | - |
| Accounts Payable (%) | ||||||||||
| Capital Expenditure | -0.21 | - | - | - | - | - | - | - | - | - |
| Capital Expenditure (%) |
Weighted Average Cost Of Capital
| Share price | $ 0.05 |
|---|---|
| Beta | 0.233 |
| Diluted Shares Outstanding | 4.99 |
| Cost of Debt | |
| Tax Rate | 52.42 |
| After-tax Cost of Debt | -593.60% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 5.538 |
| Total Debt | 1.67 |
| Total Equity | 0.25 |
| Total Capital | 1.92 |
| Debt Weighting | 86.97 |
| Equity Weighting | 13.03 |
| Wacc |
Build Up Free Cash
Year A/P | 2018 Actual | 2019 Projected | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 22.25 | - | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|---|---|
| EBITDA | -57.28 | - | - | - | - | - | - | - | - | - |
| EBIT | -57.79 | - | - | - | - | - | - | - | - | - |
| Tax Rate | 5.78% | 3.91% | 1.79% | -43.66% | 52.42% | 4.05% | 4.05% | 4.05% | 4.05% | 4.05% |
| EBIAT | -54.45 | - | - | - | - | - | - | - | - | - |
| Depreciation | 0.51 | - | - | - | - | - | - | - | - | - |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventories | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Capital Expenditure | -0.21 | -0.01 | -0.06 | -0.15 | -0.13 | - | - | - | - | - |
| UFCF | -54.16 | - | - | - | - | - | - | - | - | - |
| WACC | ||||||||||
| PV UFCF | - | - | - | - | - | - | - | - | - | |
| SUM PV UFCF | - |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | -515.53 |
| Free cash flow (t + 1) | - |
| Terminal Value | - |
| Present Value of Terminal Value | - |
Intrinsic Value
| Enterprise Value | - |
|---|---|
| Net Debt | -23.79 |
| Equity Value | - |
| Shares Outstanding | 4.99 |
| Equity Value Per Share | - |